Skip to main content

Sitagliptin (International)

In the US, Sitagliptin (sitagliptin systemic) is a member of the drug class dipeptidyl peptidase 4 inhibitors and is used to treat Type 2 Diabetes.

US matches:

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

A10BH01

CAS registry number (Chemical Abstracts Service)

0486460-32-6

Chemical Formula

C16-H15-F6-N5-O

Molecular Weight

407

Therapeutic Category

Oral antidiabetic agent: Dipeptidyl peptidase-4 (DPP-4) inhibitor, gliptin

Chemical Names

(R)-3-Amino-1-[3-(trifluormetyl)-5,6,7,8-tetrahydro[1,2,4]triazol[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorphenyl)butan-1-on (IUPAC)

(3R)-3-Amino-1-[3-(trifluorometyl)-5,6,7,8-tetrahydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one (WHO)

Foreign Names

Generic Names

Brand Names

Glossary

TermDefinition
BANBritish Approved Name
BANMBritish Approved Name (Modified)
IUPACInternational Union of Pure and Applied Chemistry
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
PHPharmacopoeia Name
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Further information on drug naming conventions: International Nonproprietary Names.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Search international drugs